Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / July 19, 2024 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money show, a sponsored program on Bloomberg TV, this Saturday, July 20, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
RedChip Companies將於本週六美國東部時間晚上7點在Bloomberg電視臺上播出採訪Enlivex Therapeutics Ltd.（納斯達克：ENLV）和Biotricity，Inc.（納斯達克：BTCY）的節目RedChip Small Stocks, Big Money show。Bloomberg電視臺在美國約7300萬戶家庭中可接收。
Access the interviews in their entirety at:
Soligenix:
Enlivex Therapeutics:
Biotricity:
Enlivex Therapeutics:
Biotricity:
Oren Hershkovitz, Ph.D., CEO of Enlivex Therapeutics, appears on the RedChip Small Stocks, Big Money show on Bloomberg TV to provide a corporate update. Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing AllocetraTM, a universal, off-the-shelf cell therapy designed to reprogram macrophages, which are primary immune cells, into their homeostatic state. Diseases such as osteoarthritis, sepsis, and many others reprogram macrophages out of their homeostatic state. These nonhomeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, Allocetra has the potential to provide a novel immunotherapeutic mechanism of action and resolution for conditions which are life threatening and debilitating "unmet medical needs".
Enlivex Therapeutics的CEO Oren Hershkovitz博士將在Bloomberg電視臺的RedChip Small Stocks, Big Money show中提供公司動態更新。Enlivex是一家臨床階段的巨噬細胞重編程免疫治療公司，正在開發AllocetraTm，這是一種通用的現成細胞治療方案，旨在重新編程主要免疫細胞巨噬細胞回到它們的穩態狀態。疾病如骨關節炎、敗血症和許多其他疾病會使巨噬細胞失去穩態，而這些非穩態巨噬細胞會嚴重加劇相關疾病的嚴重程度。通過恢復巨噬細胞的穩態，Allocetra具有提供一種新型的免疫治療機制和解決方案的潛力，適用於威脅生命和造成嚴重影響的“未滿足醫療需求”條件。
In an exclusive interview, Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity, will share insight into the company's innovative portfolio of cardiac monitoring solutions, which includes the FDA-cleared Bioflux and Biocore devices, targeting a total addressable market of $35 billion. With its solutions utilized daily by cardiologists across 34 states and 500 centers, Biotricity has captured an 8% market share in cardiology, bolstered by high retention rates of approximately 99% and a recurring revenue base that boasts strong LTV-to-CAC ratios. Biotricity is on a clear path to profitability and expects to be EBITDA positive before the end of 2024.
在一次獨家採訪中，Biotricity的創始人兼首席執行官Dr. Waqaas Al-Siddiq將分享該公司創新心臟監測解決方案的見解，其中包括FDA認證的Bioflux和Biocore設備，瞄準總可尋址市場達35億美元。隨着其解決方案每天被34個州和500箇中心的心臟病專家使用，Biotricity已經在心臟病學領域佔據了8%的市場份額，高維持率約爲99%和強有力的LTV-to-CAC比率的不斷增長的再生收入基礎也爲此提供了支撐。Biotricity正在走向盈利，預計在2024年底之前實現EBITDA盈利。
About Enlivex Therapeutics Ltd.
關於Enlivex Therapeutics Ltd.
Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information, visit .
Enlivex是一家臨床階段的巨噬細胞重編程免疫治療公司，正在開發Allocetra，這是一種通用的現成細胞治療方案，旨在重新編程巨噬細胞回到其穩態狀態。重置非穩態巨噬細胞的穩態狀態對於免疫系統的重新平衡和解決威脅生命的疾病非常重要。更多信息，訪問 。
About Biotricity
關於Biotricity
Biotricity is transforming the healthcare market by bridging the gap in remote monitoring and chronic care management with a focus on cardiology. Physicians and patients trust Biotricity's unparalleled standard for preventive and personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit and follow us on Twitter and LinkedIn.
Biotricity正在通過實現遙測與慢性病管理之間的進一步連接，集中於心臟學領域，以此來改變保健市場。醫生和病人都信任Biotricity的預防性護理和個人護理的卓越標準，包括針對慢性疾病的診斷和後診斷解決方案。該公司開發了全面的面向醫療和消費市場的遠程健康監測解決方案。詳情請訪問，同樣您也可以關注我們的 Twitter 和 LinkedIn。
About RedChip Companies
關於RedChip公司
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 32 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
RedChip公司是一家國際投資關係、媒體和研究公司，專注於微型股和小型股公司。30多年來，RedChip爲客戶提供了具體的、可量化的結果。我們的每週在線報告《Small Stocks，Big Money》每週在線投資者共計60,000人。RedChip已經發展成爲行業中最全面的服務平台，爲微型庫存和小型庫存提供以下服務：爲其股票調查提供遍佈全球的分銷網絡；在美國主要城市進行零售和機構路演；對股票經紀人、RIA、機構和家族辦公室進行出口推廣；數字媒體投資者關係平台，已經產生了數百萬獨特的投資者瀏覽量；爲投資者舉辦網絡研討會和小組電話；電視節目《Small Stocks, Big Money》每週在Bloomberg US播出，本地和全國市場的電視廣告；公司和產品視頻；網站設計；和傳統的投資者關係服務，包括新聞稿撰寫、投資者演示文稿開發、季度電話會議劇本撰寫、戰略諮詢、籌資等。
To learn more about RedChip's products and services, please visit:
要了解更多有關RedChip的產品和服務的信息，請訪問：
"Discovering Tomorrow's Blue Chips Today"
“發現明日的藍籌股”
Follow RedChip on LinkedIn:
在LinkedIn上關注RedChip：
Follow RedChip on Facebook:
在Facebook上關注RedChip：
Follow RedChip on Instagram:
在Instagram上關注RedChip：
Follow RedChip on Twitter:
在Twitter上關注RedChip：
Follow RedChip on YouTube:
在YouTube上關注RedChip：
Follow RedChip on Rumble:
在Rumble上關注RedChip：
Subscribe to our Mailing List:
訂閱我們的郵件列表：
Contact:
聯繫方式：
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com
--END--
--END--
SOURCE: RedChip
來源：RedChip
譯文內容由第三人軟體翻譯。